Vanta Bioscience Ltd — Board Meeting, 01-08-2025: Board Meeting

Vanta Bioscience's board has approved its audited standalone and consolidated financial results for the half-year and year ended March 31, 2025. For the full year, standalone revenue reached 1.13 Cr with a net loss of 2.66 Cr. On a consolidated basis, revenue was 1.96 Cr, showing a net loss of 4.77 Cr. The company's statutory auditors issued an unmodified opinion on both sets of results. This disclosure provides crucial annual financial insights for shareholders, clarifying the company's performance for the latest fiscal period.